Silence Therapeutics has unveiled Michael Khan as the company's new Chief Medical Officer.
He will oversee the phase II study on ATU027 for cancer and aid in the expansion of the private biotechnology company's clinical pipelines in oncology and acute lung injury.
Khan is a consultant endocrinologist at University Hospitals of Coventry and Warwickshire. He is also an associate professor of medicine at the University of Warwick.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Last September he became a director and chief medical adviser at Silence Therapeutics, which develops systematic RNA interference therapeutics for the treatment of cancer and other diseases.
"These are very exciting times for Silence Therapeutics, with one oncology drug advancing to phase II," he said in a statement.
"Moreover, with a range of new indications in the pipeline, I am really happy to be a part of this dynamic new enterprise."
Ali Mortazavi, director of Corporate Strategy, added: "I'm delighted Mike has decided to devote more time to us. Next year will be pivotal for Silence after so many years spent preparing for phase II trials."
Shares jumped 9.71% to 4.80p at 12:39 Wednesday.
RD
-
Three bargain investment trusts to add to your portfolioThese three investment trusts are bargains compared to their net asset value (NAV), but one fund analyst thinks the deep discounts are unwarranted.
-
Premium Bond prize fund rate to be cut again to 4%NS&I will reduce the Premium Bond rate from 4.15% to 4% in January, while also cutting the rates on other savings accounts. Are Premium Bonds still worth it?
